MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
PR Newswire•28/10/2026•08:31 ET
0
Key Highlights
- ➤DA-1726 Phase 1 data accepted for oral presentation November 4, 2026
- ➤Presentation title cites significant MRI-PDFF reduction and weight loss
- ➤32 mg dose showed best-in-class potential for weight loss and glucose control
- ➤MetaVia also develops vanoglipel for MASH treatment
Expert Statements
Sarah Browne, Chief Medical Officer of MetaVia
“DA-1726, a Dual GLP-1 and Glucagon Receptor Agonist, Leads to Significant Reduction in MRI-PDFF and Weight Loss with Relative Preservation of Lean Mass: A Randomized Placebo-Controlled Trial”
MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026 PR Newswire
CAMBRIDGE, Mass., Oct. 28, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from the Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for an oral presentation at the Precision Liver Symposium 2026, taking place November 4, 2026, in Denver, Colorado.
Get started
Create a free account to read the full story.